What ChondroFiller hip injection involves

For patients weighing up whether to pursue this route, the most practical starting point is understanding what the appointment actually looks like. ChondroFiller hip injection is an outpatient procedure carried out under local anaesthetic, without a general anaesthetic, theatre admission, or any surgical incision.

The treatment uses a CE-marked Class III injectable collagen scaffold — a liquid material injected directly into the hip joint through a needle placed under continuous ultrasound guidance. Real-time imaging is used throughout to direct the needle accurately and to keep critical nearby structures clearly in view, for reasons that the anatomy of the hip makes especially important.

Once inside the defect, the material gels within three to five minutes at body temperature, conforming to the shape of the damaged area. The result is a porous scaffold that supports the body's own repair processes at the site of the cartilage damage. Most patients leave the clinic on the same day, typically within a few hours of arrival.

How the scaffold supports cartilage repair

The scaffold itself contains no donor cells — ChondroFiller is an acellular Type I collagen hydrogel, so the biological repair work is done entirely by the patient's own body.

Once the material gels inside the defect, its porous three-dimensional structure acts as a chemotactic signal, drawing the patient's own mesenchymal progenitor cells in from surrounding tissue — synovium, subchondral bone, and joint fluid. Those recruited cells migrate into the scaffold, mature into chondrocytes (the specialised cells responsible for maintaining cartilage), and begin producing new cartilage matrix. As that process continues, the collagen scaffold is gradually resorbed and replaced by the body's own tissue.

This mechanism — known as acellular matrix-induced chondrogenesis — is supported by laboratory data. A 2025 ex vivo study using human osteochondral tissue recorded a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, indicating meaningful cell recruitment into the scaffold within the first two weeks. That finding supports the cell-recruitment pathway, though ex vivo data alone cannot predict individual clinical outcomes.

Because the scaffold is temporary and the repair depends on how well the patient's own cells respond, who is likely to benefit from treatment — and who is not — matters considerably, and that is shaped by the specific nature of the hip damage.

Which patients are typically assessed

Broadly speaking, ChondroFiller hip injection suits patients with a localised area of cartilage damage — meaning damage confined to a specific zone rather than spread across the joint. In clinical terms, that typically means full or near-full thickness loss (the deepest categories of cartilage damage, commonly graded as ICRS Grade III or IV) covering roughly 2–6 cm² in area. The hip cohort reported by Mazek et al. (2021, Journal of Hip Preservation Surgery) specifically assessed acetabular lesions greater than 2 cm², most arising from femoroacetabular impingement (FAI) — a structural mismatch at the hip that causes repeated cartilage wear over time.

The clearest exclusion boundary is the state of the wider joint. Patients who already had moderate-to-severe osteoarthritis before treatment — where significant joint-space narrowing and widespread degeneration were present — consistently achieved poor results in the published hip cohorts. This is not a product limitation; it reflects a biological reality. The scaffold works by recruiting the patient's own repair cells from surrounding tissue, and a joint whose architecture is already substantially lost cannot reliably supply that repair environment. ChondroFiller is not a treatment for advanced osteoarthritis, and specialist assessment for such patients would typically point towards other pathways.

Beyond defect size and joint condition, age, activity level, and the underlying cause of the cartilage damage all form part of an individual assessment — factors that cannot be evaluated without a clinical consultation.

What clinical evidence exists for the hip

The strongest direct evidence for ChondroFiller in the hip comes from Mazek et al. (2021, Journal of Hip Preservation Surgery) — a prospective cohort of 26 adults with femoroacetabular impingement and acetabular cartilage lesions exceeding 2 cm². At 3–5-year follow-up, 17 of 21 evaluable patients achieved good or excellent outcomes, with modified Harris Hip Score improving by approximately 30 points — a clinically meaningful gain across pain and function. A separate hip series published by Perez-Carro in 2021 independently corroborated the same patient-selection boundaries, lending consistency to the findings across two cohorts.

Across the broader ChondroFiller literature — spanning knee, hip, and smaller joint applications — published series report that roughly 70–85% of patients achieve meaningful symptom relief at 3–5 years. That headline figure sits alongside a consistent caveat: patients who had moderate-to-severe osteoarthritis before treatment achieved poor results in the hip cohort. The outcome data and the selection criteria point in the same direction.

Two evidence gaps are worth stating plainly. First, no randomised controlled trial has directly compared ultrasound-guided ChondroFiller hip injection against an unguided or sham control — all published hip data come from cohort studies. Second, follow-up beyond five years remains limited for the injectable route specifically. A specialist assessment will weigh the available cohort data alongside an individual patient's imaging, symptom profile, and joint condition before advising on suitability.

Why the hip requires ultrasound guidance

Anatomy makes the hip one of the most technically demanding joints for injection therapy. The anterior joint space — where the needle tip must land to reach a cartilage defect — lies 4–8 cm beneath the skin surface, roughly three to four times the depth of a typical knee injection. That distance alone makes accurate freehand placement unreliable, because the operator cannot confirm needle position without imaging.

The surrounding anatomy compounds the challenge. Within approximately 2 cm of the anterior hip capsule sit three major neurovascular structures: the femoral artery (approximately 1.9 cm medial to the capsule), the femoral vein (approximately 1.7 cm medial), and the femoral nerve (approximately 2.3 cm lateral). More unpredictably, the lateral circumflex femoral artery crosses directly over the anterior capsule at a position that varies between patients — a vessel that no surface landmark can reliably locate before a needle is placed.

The practical cost of these anatomical factors is well quantified. A 2016 systematic review and meta-analysis by Hoeber et al. (British Journal of Sports Medicine, cited 119 times) found that landmark-guided hip injections achieved accurate intra-articular placement in just 72% of cases (95% CI 56–85%). Ultrasound-guided injections achieved 100% (95% CI 98–100%), a difference significant at p<0.0001. In roughly one in four landmark-guided attempts, the injected material never reaches the joint space.

Precision matters particularly for ChondroFiller because the scaffold gels within 3–5 minutes of reaching body temperature and cannot be repositioned once it begins to set. Initial needle placement at the defect site is a one-shot requirement.

A 2025 retrospective series of 276 ultrasound-guided hip arthrograms, using a lateral short-axis approach, recorded 99.3% adequate intra-articular fill with zero vascular complications. Real-time colour Doppler mapping of the femoral vessels and the lateral circumflex femoral artery, combined with live needle visualisation through the full depth of soft tissue, together effectively eliminate vascular injury risk in skilled hands.

Finding a ChondroFiller hip specialist in the UK

Specialists offering ultrasound-guided ChondroFiller hip injection are found across the UK, typically within MSK medicine, sports medicine, and image-guided injection practices — it is not a procedure confined to a single centre.

When searching for the right clinician, it is worth looking for someone whose practice covers both cartilage-focused injection therapies and image-guided hip procedures specifically. Useful questions to raise at consultation include:

• What patient selection criteria do you apply, and how do you assess defect size and overall joint health before proceeding?
• What imaging or pre-procedure assessment do you use to confirm suitability?
• What weight-bearing and rehabilitation protocol do you recommend after the injection?

A thorough pre-procedure assessment — covering joint architecture, defect characteristics, and osteoarthritis grade — is, as the evidence reviewed above makes clear, as important as the injection itself.

Search MSK is a UK specialist directory covering MSK and sports-medicine clinicians; it can be filtered by region and specialty to identify practitioners who offer ChondroFiller hip injection near you.